Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

The UWMDI is the first of its kind in the Pacific Northwest, integrating state-of-the-art research programs with superb care for patients with diabetes, obesity and their complications ...

In December 2024, the Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

Former BBC Radio 4 presenter Dame Jenni Murray has bravely opened up on the lasting impact her mother's obsession with weight ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Oprah's perception of other people's habits isn't the only thing to have changed with the introduction of the weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...